Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Vaccines specialty page provides vaccine-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Exploring Cephalosporin/β-Lactamase Inhibitor Combinations for Treatment of <i>Pseudomonas</i>
Peter Salgo, MD; Yoav Golan, MD; Andrew Shorr, MD; and Marin Hristos Kollef, MD, provide their perspective on the cephalosporin/β-lactamase inhibitor combinations Zerbaxa, Avycaz, and Vabomere, with considerations for mechanisms of action and effectiveness.
Measles Outbreak at England High School Emphasizes the Need for Vaccination
Following recent reports that England has seen more measles cases so far in 2018 than in all of 2017, health officials are combating outbreaks of the virus with vaccination clinics.
Junin Virus Vaccine Antibodies Can Also Fight Machupo Virus
Researchers have found that a vaccine for Junin virus, a South American hemorrhagic fever virus, protects against another virus in the same family, opening up the possibility for universal vaccines for virus families.
Top Infectious Disease News of the Week—May 6, 2018
In case you missed them, we've compiled the top 5 articles from this past week.
Universal Influenza Vaccine Candidate to Begin Clinical Trial in United States
A phase 2 trial of an experimental universal flu vaccine is moving forward with sponsorship from The National Institute of Allergy and Infectious Diseases.
Significant Enrollment Milestone Met in Phase 3 Trial of Novavax's RSV Vaccine
Novavax announces that enrollment in phase 3 Prepare trial has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F vaccine.
PaxVax Chikungunya Vaccine Granted Fast Track Designation by FDA
If clinical development progresses, the PaxVax vaccine could potentially become the first vaccine approved by the FDA for the prevention of chikungunya.
Single-Dose Of Ebola Vaccine May Provide Protection Against Deadly Disease for Up to 2 Years
A recent study has found that a single-dose of Merck's Ebola vaccine delivers antibodies that can last for 1 to 2 years.
Big advances in treatment can